The Pharmaceuticals and Medical Devices Agency (PMDA) announced that the SHINSA companion diagnostic (CDx) has received approval for use in identifying patients who are eligible for certain treatments. The approval was updated on June 16, 2026. Further details are available on the PMDA website.
Regulatory UpdatesAug 23, 2026•1 min read
PMDA Approves SHINSA CDx for Identifying Eligible Patients
Japan’s PMDA has approved the SHINSA companion diagnostic (CDx) to help identify patients eligible for specific therapies, updated June 16, 2026.
Compiled by the PharmaCountry team · Source: PMDA Japan
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating